Intuitive Surgical stock trades near record territory as robotic surgery growth supports valuation

Intuitive Surgical stock, tied to Intuitive Surgical Inc. (ISIN US46120E6023) and listed on Nasdaq, is backed by robust fundamentals as the company continues to expand its installed base of robotic surgery systems and recurring revenue streams from procedures and instruments. In its most recently reported full fiscal year, Intuitive Surgical disclosed multi-billion dollar revenue and strong margins for 2025 according to its investor relations information as published on 15 February 2026 on the company website, underlining the earnings power behind the current valuation.

Revenue grows in double digits

According to Intuitive Surgical's investor relations materials for fiscal 2025, the company reported total revenue in the range of several billion dollars, representing a clear double-digit percentage increase compared with fiscal 2024, driven primarily by growth in minimally invasive procedures performed with the da Vinci Surgical System. The company highlighted that instrument and accessory revenue, which is closely linked to procedure volume, increased at a faster rate than system sales in 2025, underscoring the importance of recurring revenue for long term cash generation. In its management commentary, Intuitive Surgical pointed out that procedure volumes increased at a double-digit rate year over year in 2025, reflecting broader adoption of robotic-assisted surgery in urology, gynecology, and general surgery while improving utilization of the installed system base.

Operating income and net income also expanded in fiscal 2025 compared with 2024 as Intuitive Surgical managed to grow revenue faster than operating expenses, according to the same investor relations report released in early 2026. The company emphasized that gross margin remained high, supported by the mix of high-margin instruments and accessories, while investment in research and development and market expansion continued. Management noted that recurring revenue, including service contracts and usage-based fees, represented a substantial portion of total revenue in 2025, providing improved visibility into future cash flows and supporting the investment case behind Intuitive Surgical stock.

Procedure growth above prior year

In its commentary on clinical usage, Intuitive Surgical reported that overall procedure volume performed on the da Vinci Surgical System increased at a double-digit percentage rate in 2025 versus 2024, with certain specialties such as general surgery growing even faster according to the investor update. This quantified comparison between 2025 and 2024 procedures suggests that the adoption curve for robotic-assisted surgery remains in an expansion phase, which can lead to further increases in the consumption of instruments and accessories per procedure. The company also indicated that the global installed base of da Vinci systems grew in 2025 compared with 2024, as hospitals and surgical centers continued to invest in capital equipment to broaden their minimally invasive surgery capabilities.

Management stressed that international markets contributed a larger share of growth in 2025 than they did in 2024, with procedure volumes outside the United States expanding at a strong pace according to the same investor relations materials. This geographic diversification helps reduce reliance on a single health care market and can mitigate policy or reimbursement changes in individual countries. For investors, the combination of higher procedure volumes, a growing installed base, and expanding international exposure provides a multi-layered growth story behind Intuitive Surgical stock, even as the company navigates regulatory and competitive dynamics in the medical technology sector.

da Vinci surgery system drives recurring revenue

The da Vinci Surgical System, Intuitive Surgical's flagship robotic platform, is central to the company's business model because it links capital equipment sales with recurring revenue from instruments and accessories. Intuitive Surgical explained in its annual report that hospitals typically purchase the da Vinci system as a long term investment, and then order specialized instruments and consumables for each procedure. As a result, each additional procedure performed on a da Vinci system generates incremental revenue through instrument usage, which accumulates over time across the installed base. For investors assessing Intuitive Surgical stock, this interplay between installed system growth and procedure volume is a key driver of revenue trajectory.

The company also offers training, service, and maintenance contracts for da Vinci systems, which add another recurring revenue stream beyond per procedure instrument usage. In its investor materials for 2025, Intuitive Surgical noted that service revenue increased compared with 2024, reflecting both the larger installed base and the aging of systems that require more maintenance. The company emphasized that the reliability and uptime of da Vinci systems are crucial for hospital operations, and that its service organization works to maximize system availability for surgical teams. These operational details matter for financial analysis because they influence customer satisfaction, renewal of service contracts, and potential future upgrades to newer generations of robotic systems.

Margins and cash flow support valuation

Intuitive Surgical's gross margin remained high in fiscal 2025, similar to levels recorded in 2024, according to its investor relations disclosures. This reflects the favorable economics of instrument and accessory sales, which typically carry higher margins than hardware, and the company's ability to manage production costs. Operating margin and net margin both improved in 2025 versus 2024, driven by revenue growth outpacing operating expense growth. The company has consistently generated strong operating cash flow, which in 2025 exceeded prior year levels according to its financial statements, providing resources for continued investment in research and development and for potential capital allocation decisions such as share repurchases.

In reviewing the company's financial profile, analysts often compare Intuitive Surgical's margin structure with other medical technology and equipment companies. Intuitive Surgical's combination of high gross margins and robust operating margins places it among the stronger performers in the sector, underscoring why Intuitive Surgical stock commands a premium valuation relative to many peers. At the same time, the company faces ongoing needs to invest in new technologies, regulatory compliance, and clinical evidence to sustain its leadership in robotic-assisted surgery, which can influence future expense patterns and capital requirements.

Shares reflect long term growth expectations

The stock market tends to value Intuitive Surgical based on expectations for long term growth in minimally invasive robotic procedures rather than short term fluctuations. As of a recent quote in mid 2026, Intuitive Surgical stock traded in the several-hundred dollar range per share on Nasdaq, near record territory over the prior twelve month period, according to major US exchange data providers. This positioning near historical highs is consistent with the company having delivered sustained double-digit revenue growth and expanding margins in recent years. The valuation implicitly reflects expectations that procedure volumes will continue to grow and that Intuitive Surgical will maintain its competitive position against other emerging robotic surgery offerings.

For investors analyzing the stock, the relationship between share price levels and underlying financial metrics such as revenue, earnings, and cash flow is central. While Intuitive Surgical's share price involves market sentiment and risk considerations, the company's tracked performance in 2025 compared with 2024 provides a concrete basis for assessing whether the valuation is supported by fundamental trends. The quantified comparisons in revenue growth, margin expansion, and procedure volume increases all feed into broader models that evaluate Intuitive Surgical stock within diversified portfolios, particularly among health care and technology subsectors.

Product focus on da Vinci platform

Intuitive Surgical's primary commercial product is the da Vinci Surgical System, which integrates robotic arms, high definition imaging, and surgeon consoles to enable minimally invasive procedures. The system is used across a range of specialties, including urology, gynecology, thoracic surgery, and general surgery, with indications expanding as clinical evidence develops. The company's latest generation systems offer improved ergonomics, imaging, and instrumentation compared with earlier versions, and Intuitive Surgical has reported adoption of these newer platforms as hospitals upgrade their equipment. The revenue contribution from newer da Vinci systems and associated instruments forms part of the growth narrative underlying Intuitive Surgical stock.

Stock level and key data

Intuitive Surgical stock recently traded on Nasdaq at a level in the several-hundred dollar range per share in USD, based on quotes from major US market data portals as of mid 2026. This places the share price close to its historical highs over the prior year, a reflection of investor confidence in the company's ability to grow its installed base and procedure volumes. Market capitalization correspondingly stood in the tens of billions of dollars range in USD as of the same date, underscoring Intuitive Surgical's status as a large cap health care technology company. Despite the high valuation, the company's strong margins and recurring revenue streams contribute to investor perceptions of resilience in its business model.